These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 27158766)
1. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein. Werner-Allen JW; DuMond JF; Levine RL; Bax A Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766 [TBL] [Abstract][Full Text] [Related]
2. Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein. Werner-Allen JW; Monti S; DuMond JF; Levine RL; Bax A Biochemistry; 2018 Mar; 57(9):1462-1474. PubMed ID: 29394048 [TBL] [Abstract][Full Text] [Related]
3. Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein. Werner-Allen JW; Levine RL; Bax A Biochem Biophys Res Commun; 2017 May; 487(2):281-286. PubMed ID: 28412346 [TBL] [Abstract][Full Text] [Related]
4. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411 [TBL] [Abstract][Full Text] [Related]
5. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850 [TBL] [Abstract][Full Text] [Related]
6. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103 [TBL] [Abstract][Full Text] [Related]
7. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Rees JN; Florang VR; Eckert LL; Doorn JA Chem Res Toxicol; 2009 Jul; 22(7):1256-63. PubMed ID: 19537779 [TBL] [Abstract][Full Text] [Related]
9. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain. Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215 [TBL] [Abstract][Full Text] [Related]
10. The catecholaldehyde hypothesis: where MAO fits in. Goldstein DS J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952 [TBL] [Abstract][Full Text] [Related]
11. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942 [TBL] [Abstract][Full Text] [Related]
12. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867 [TBL] [Abstract][Full Text] [Related]
15. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Goldstein DS; Kopin IJ; Sharabi Y Pharmacol Ther; 2014 Dec; 144(3):268-82. PubMed ID: 24945828 [TBL] [Abstract][Full Text] [Related]
16. The heart of PD: Lewy body diseases as neurocardiologic disorders. Goldstein DS; Sharabi Y Brain Res; 2019 Jan; 1702():74-84. PubMed ID: 29030055 [TBL] [Abstract][Full Text] [Related]
17. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde. Lima VA; do Nascimento LA; Eliezer D; Follmer C ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158 [TBL] [Abstract][Full Text] [Related]
18. Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified α-synuclein. Carmo-Gonçalves P; do Nascimento LA; Cortines JR; Eliezer D; Romão L; Follmer C Biochem Biophys Res Commun; 2018 Oct; 505(1):295-301. PubMed ID: 30249394 [TBL] [Abstract][Full Text] [Related]
19. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease. Burke WJ Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):143-8. PubMed ID: 12769806 [TBL] [Abstract][Full Text] [Related]
20. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know. Goldstein DS Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]